- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06561958
Studio prospettico, multicentrico, non interventistico per indagare l'efficacia di REKOVELLE® per la stimolazione ovarica per le donne asiatiche in contesti del mondo reale (PROFOUND)
Studio prospettico, multinazionale, non interventistico per indagare REKOVELLE per la stimolazione ovarica: efficacia, sicurezza e modelli di utilizzo per le donne asiatiche nella pratica del mondo reale
Primary objective is to investigate the effectiveness of REKOVELLE® in women undergoing their first REKOVELLE® ovarian stimulation treatment in real world practice in Asian countries.
Panoramica dello studio
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Busan, Corea del Sud, 47245
- Ferring Investigational Site
-
Seoul, Corea del Sud, 02586
- Maria Fertility Hospital
-
-
Busan
-
Busan, Busan, Corea del Sud, 49241
- Ferring Investigational Site
-
-
Daegu
-
Daegu, Daegu, Corea del Sud, 41910
- Ferring Investigational Site
-
-
Seongnam
-
Seongnam-si, Seongnam, Corea del Sud, 13496
- Ferring Investigational Site
-
-
-
-
-
Hiroshima, Giappone, 7300035
- Ferring Investigational Site
-
Hokkaido, Giappone, 0600003
- Ferring Investigational Site
-
Hyōgo, Giappone, 6500021
- Ferring Investigational Site
-
Osaka, Giappone, 5300011
- Ferring Investigational Site
-
Osaka, Giappone, 5500015
- Ferring Investigational Site
-
Saitama, Giappone, 3540035
- Ferring Investigational Site
-
-
Chiba
-
Chiba, Chiba, Giappone, 2610023
- Ferring Investigational Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Giappone, 8120013
- Ferring Investigational Site
-
Kitakyushu, Fukuoka, Giappone, 8070825
- Ferring Investigational Site
-
-
Gunma
-
Takasaki, Gunma, Giappone, 3700841
- Ferring Investigational Site
-
-
Hiroshima
-
Hiroshima, Hiroshima, Giappone, 7320822
- Ferring Investigational Site
-
-
Japan
-
Bunkyō City, Japan, Giappone, 1130033
- Ferring Investigational Site
-
-
Tokyo
-
Tokyo, Tokyo, Giappone, 1600023
- Ferring Investigational Site
-
-
-
-
-
Bangkok, Tailandia, 10700
- Ferring Investigational Site
-
-
Muang
-
Phitsanulok, Muang, Tailandia, 65000
- Naresuan University Hospital
-
-
Ratchathewi
-
Bangkok, Ratchathewi, Tailandia, 10400
- Ramathibodi Hospital
-
-
-
-
-
Taichung, Taiwan, 406
- Ferring Investigational Site
-
Taipei, Taiwan, 100225
- Ferring Investigational Site
-
Taipei, Taiwan, 110
- Ferring Investigational Site
-
-
Tainan
-
Tainan, Tainan, Taiwan, 70403
- Ferring Investigational Site
-
Tainan, Tainan, Taiwan, 71004
- Ferring Investigational Site
-
-
Taoyuan
-
Taoyuan, Taoyuan, Taiwan, 333
- Ferring Investigational Site
-
-
-
-
Hanoi
-
Hanoi, Hanoi, Vietnam, 100000
- Ferring Investigational Site
-
-
Ho Chi Minh City
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam, 700000
- Ferring Investigational Site
-
Ho Chi Minh City, Ho Chi Minh City, Vietnam
- Ferring Investigational Site
-
-
Huế
-
Huế, Huế, Vietnam, 49000
- Ferring Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Approximately 1500 patients prescribed REKOVELLE for the first time for controlled overian stimulation (COS) will be enrolled in the study.
Descrizione
Inclusion Criteria:
- Females aged 20 years or older at enrollment
- Serum AMH level >0.5 ng / mL (with the latest result tested within 12 months)
- Who are first time prescribed REKOVELLE for their ovarian stimulation and IVF or ICSI treatment cycle using fresh or frozen ejaculated sperm from male partner or sperm donor (if applicable)
- Willing and able to provide written informed consent
Exclusion Criteria:
- Have undergone more than 2 COS-IVF / ICSI cycles before the enrollment
- Participating in an interventional clinical trial in which any medication treatment is mandated
- Women with a contraindication for prescription of REKOVELLE treatment
- Oocyte donors
- Undergoing ovarian stimulation for fertility preservation
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
REKOVELLE
Participants prescribed REKOVELLE for the first time for controlled ovarian stimulation. |
Individualised dosing regiment of REKOVELLE in routine clinical practice. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Cumulative live birth rate
Lasso di tempo: Up to 12 months
|
Cumulative live birth rate defined as delivery of at least 1 live fetus after 20 completed weeks of gestation, combined fresh and frozen embryo transfers within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
Up to 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
The Luteinising hormone (LH) surge suppression protocol
Lasso di tempo: Up to 22 days
|
Treatment pattern will be measured by analysing the Lutenising hormone (LH) surge suppression protocol. |
Up to 22 days
|
|
Daily Dosage
Lasso di tempo: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of daily dosage. |
Up to 22 days
|
|
Stimulation Duration
Lasso di tempo: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of stimulation duration. |
Up to 22 days
|
|
Total Dosage
Lasso di tempo: Up to 22 days
|
Treatment pattern will be measured by analysing the REKOVELLE and concomitant ovarian stimulation protocols, consisting of total dosage. |
Up to 22 days
|
|
Trigger Protocol
Lasso di tempo: Up to 22 days
|
Treatment pattern will be measured by analysing the trigger protocol. |
Up to 22 days
|
|
Luteal phase support protocol
Lasso di tempo: Up to 22 days
|
Treatment pattern will be measured by analysing the luteal phase support protocol. |
Up to 22 days
|
|
Number of oocytes retrieved
Lasso di tempo: Up to 22 days
|
Number of oocytes retrieved at oocyte retrieval |
Up to 22 days
|
|
Number of Metaphase II (MII) oocytes
Lasso di tempo: Up to 22 days
|
Number of MII oocytes at oocyte retrieval (only applicable for Intracytoplasmic sperm injection (ICSI)) |
Up to 22 days
|
|
Number of embryos
Lasso di tempo: Day 3 after oocyte retrieval
|
Number of embryos on Day 3 after oocyte retrieved |
Day 3 after oocyte retrieval
|
|
Number of Blastocysts
Lasso di tempo: Day 5 after oocyte retrieval
|
Number of Blastocysts on Day 5 after oocyte retrieved |
Day 5 after oocyte retrieval
|
|
Number of embryos transferred
Lasso di tempo: Up to 28 days
|
Embryos transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Number of blastocysts transferred
Lasso di tempo: Up to 28 days
|
Blastocysts transferred in fresh and/or frozen transfer cycles |
Up to 28 days
|
|
Implantation rate
Lasso di tempo: Up to 28 days
|
Number of gestational sacs, embryos or blastocysts transferred |
Up to 28 days
|
|
Positive human chorionic gonadotropin (hCG) rate
Lasso di tempo: 11 to 15 days after transfer
|
Positive human chorionic gonadotropin (hCG) rate analysed using serum or urine hCG test 11-15 days after transfer |
11 to 15 days after transfer
|
|
Clinical Pregnancy rate
Lasso di tempo: 4 to 5 weeks after transfer
|
Clinical pregnancy rate (at least 1 gestational sac 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Vital Pregnancy
Lasso di tempo: 4 to 5 weeks after transfer
|
Vital pregnancy rate (at least 1 intrauterine gestational sac with fetal heartbeat 4-5 weeks after transfer) |
4 to 5 weeks after transfer
|
|
Ongoing pregnancy rate
Lasso di tempo: 9 to 11 weeks after transfer
|
Ongoing pregnancy rate (at least 1 intrauterine viable fetus 9-11 weeks after transfer) |
9 to 11 weeks after transfer
|
|
Time to pregnancy
Lasso di tempo: 4 to 5 weeks after transfer
|
Time to pregnancy from start date of ovarian stimulation to confirmation of clinical pregnancy |
4 to 5 weeks after transfer
|
|
Live birth rate
Lasso di tempo: More than 20 weeks after transfer
|
Live birth is defined as delivery of at least 1 live fetus after 20 completed weeks of gestation within 12 months after the start of the ovarian stimulation in patients of the first REKOVELLE ovarian stimulation cycle. |
More than 20 weeks after transfer
|
|
Multiple pregnancy rate
Lasso di tempo: 4 to 5 weeks after transfer
|
More than 1 gestational sac with fetal heart beat 4-5 weeks after transfer |
4 to 5 weeks after transfer
|
|
Spontaneous abortion rate
Lasso di tempo: Up to 10-11 weeks after transfer
|
Spontaneous abortion is defined as positive hCG test but all intrauterine gestational sacs without fetal heart beat as documented by ultrasound, or there are no viable fetuses observed by ultrasound |
Up to 10-11 weeks after transfer
|
|
Ectopic pregnancy rate
Lasso di tempo: Up to 10-11 weeks after transfer
|
Ectopic pregnancy is defined as extrauterine gestational sac with or without fetal heart beat as documented by ultrasound or surgery. |
Up to 10-11 weeks after transfer
|
|
Estradiol Hormone levels
Lasso di tempo: Up to 20 days
|
Estradiol hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Progesterone Hormone levels
Lasso di tempo: Up to 20 days
|
Progesterone hormone levels before stimulation and at the end of stimulation day |
Up to 20 days
|
|
Cycle cancellation rate and the reason for cycle cancellation
Lasso di tempo: Up to 28 days
|
Date when the investigator decides to cancel cycle before oocyte pick up (due to poor ovarian response, excessive ovarian response, any illness which prevents oocyte collection procedure, subject not taking hCG injection at the correct time, subject choice, other) or after oocyte pick-up (due to no oocytes collected, no oocytes fertilized, abnormal fertilization, abnormal embryo development, no embryo development, ovarian hyperstimulation syndrome (OHSS), subject choice, any other specified reason) |
Up to 28 days
|
|
Transfer cancellation rate and the reason for transfer cancellation
Lasso di tempo: Up to 28 days
|
Transfer cancellation rate and the reason for transfer cancellation (no embryo available for transfer, risk of OHSS, endometrium not receptive, high progesterone level, adverse event, any other specified reason for transfer cancellation). |
Up to 28 days
|
|
Frequency and severity of adverse drug reactions (ADRs) and serious adverse events (SAEs)
Lasso di tempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Frequency and severity of ADRs and SAEs as defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
|
Preventive interventions for ovarian hyperstimulation syndrome (OHSS)
Lasso di tempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
Preventive interventions decided by the investigator (Triggering of final follicular maturation with GnRH agonist and fresh embryo/blastocyst transfer or cryopreservation, Cancellation of fresh embryo/blastocyst transfer) |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer.
|
|
Number of subjects with mild / moderate / severe ovarian hyperstimulation syndrome (OHSS)
Lasso di tempo: During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Number of subjects with mild / moderate / severe OHSS, defined by the investigator |
During 1st cycle with REKOVELLE (each cycle range is 5-20 days, average 9 days), Up to 10-11 weeks after transfer
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Global Clinical Compliance, Ferring Pharmaceuticals
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 000430
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .